Article Details
Retrieved on: 2021-04-20 12:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Fewer than 40% of patients with chronic lymphocytic leukemia (CLL) had an adequate immune response to two doses of the Pfizer/BioNTech ...
Article found on: www.medpagetoday.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here